Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Chu Myung Seong"'
Autor:
Kyoo Hyung Lee, June-Won Cheong, Young Don Joo, Byung Soo Kim, Yoo Hong Min, Hyeok Shim, Chul Won Jung, Deog Yeon Jo, Ho Young Kim, Hwi Joong Yoon, Chi Young Park, Chul Soo Kim, Sung-Soo Yoon, Myung Soo Hyun, Chu Myung Seong, Jae Hoon Lee, Joo-Seop Chung, Hyeoung Joon Kim, Hee Sook Park, Sang Kyun Sohn
Publikováno v:
Transfusion. 54:1542-1551
Background Transfusional iron overload and its consequences are challenges in chronically transfused patients with myelodysplastic syndromes (MDSs) or aplastic anemia (AA). Study Design and Methods This was a prospective, multicenter, open-label stud
Autor:
Myung-Ju Ahn, Young Yeul Lee, Seock-Ah Im, Soon Nam Lee, Jung Hye Choi, In Soon Kim, Il Young Choi, Ho Suk Oh, Bong Seog Kim, Chu Myung Seong, Yeung-Chul Mun, Heung Woo Lee
Publikováno v:
Cancer research and treatment. 35(3)
PURPOSE Gemcitabine and 5-fluorouracil (5-FU) are two compounds with reproducible activity against advanced pancreatic carcinomas. To evaluate the activity and feasibility of this combination chemotherapy, a multi-institutional phase II study was per
Autor:
Kyung Ja Lee, Do Yeun Kim, Chu Myung Seong, Eun Mi Nam, Seock-Ah Im, Soon Nam Lee, Kyung Eun Lee, He Jin Lee, Seung Hyun Nam
Publikováno v:
Cancer Research and Treatment. 33:250-255
PURPOSE Brain metastasis is estimated to occur in 20~40% of solid tumor patients and the most common primary tumor is lung cancer. Even though the prognosis of brain metastasis is grave and the 1-year survival rate is only 15%, symptom palliations ar
Autor:
W. K. A. Yung, Si Nae Lee, Seock Ah Im, Candelaria Gomez-Manzano, Min Sun Cho, Ta Jen Liu, Y. K. Hong, Chu-Myung Seong, Jae Sik Kim, Juan Fueyo
Publikováno v:
British Journal of Cancer
Increased expression of VEGF in several types of tumours has been shown to correlate with poor prognosis. We used a replication-deficient adenoviral vector containing antisense VEGF cDNA (Ad5CMV-αVEGF) to down-regulate VEGF expression and increase t
Autor:
Myong Joon Hahn, Ju Young Seoh, Kyung Ha Ryu, Seung Cheol Kim, Wha Soon Chung, So Youn Woo, Chu Myung Seong, Hae Young Park, Eun Seon Yoo, Yong Mook Choi
Publikováno v:
British Journal of Haematology. 105:1034-1040
We investigated the phenotypic changes of human umbilical cord blood (CB) CD34+ cells during ex vivo expansion using thrombopoietin (TPO), flt3-ligand (FL), and/or granulocyte-colony stimulating factor (G-CSF). During ex vivo expansion of CD34+ cells
Autor:
June-Won, Cheong, Hyeoung-Joon, Kim, Kyoo-Hyung, Lee, Sung-Soo, Yoon, Jae Hoon, Lee, Hee-Sook, Park, Ho Young, Kim, Hyeok, Shim, Chu-Myung, Seong, Chul Soo, Kim, Jooseop, Chung, Myung Soo, Hyun, Deog-Yeon, Jo, Chul Won, Jung, Sang Kyun, Sohn, Hwi-Joong, Yoon, Byung Soo, Kim, Young-Don, Joo, Chi-Young, Park, Yoo Hong, Min
Publikováno v:
Transfusion. 54(6)
Transfusional iron overload and its consequences are challenges in chronically transfused patients with myelodysplastic syndromes (MDSs) or aplastic anemia (AA).This was a prospective, multicenter, open-label study to investigate the efficacy of defe
Autor:
Chul Won Jung, Keun Seok Lee, Chu Myung Seong, Jin Seok Ahn, Seonyang Park, Seock-Ah Im, Jong-Seok Lee, Moon Hee Lee, Soo Mee Bang, Byoung Kook Kim, Eun Kyung Cho, Chul Soo Kim, Jae Hoon Lee, Hugh C. Kim, Myung Ju Ahn, Jung Ae Lee, Sung-Soo Yoon
Publikováno v:
The Korean Journal of Internal Medicine
Background To compare the mobilizing effects and toxicities of two different doses of cyclophosphamide (CY) plus lenograstim (glycosylated G-CSF), we performed a prospective randomized study by enrolling patients suffering with either high-risk Non-H
Autor:
Sung-Soo Yoon, Samyong Kim, Yoon-Goo Kang, Jae Hoon Lee, Doyeun Oh, Seonyang Park, Chu Myung Seong, Cheolwon Suh, Hugh C. Kim, Myung Ju Ahn, Soo Mee Bang, Eun Kyung Cho, Young Suk Park, Chul Won Jung, Kyung Sam Cho
Publikováno v:
Journal of Korean Medical Science
We conducted a phase II multicenter trial to estimate the response and survival of patients with newly diagnosed multiple myeloma to high dose melphalan therapy followed by autologous peripheral blood stem cell transplantation. Eligible patients who